These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16716981)

  • 1. Octreotide in the treatment of refractory ascites of cirrhosis.
    Leong RW; Jeffrey GP
    Scand J Gastroenterol; 2006 Jun; 41(6):763; author reply 764. PubMed ID: 16716981
    [No Abstract]   [Full Text] [Related]  

  • 2. Refractory ascites due to portal vein thrombosis in liver cirrhosis--report of two cases.
    Tanaka H; Horie Y; Idobe Y; Murawaki Y; Suou T; Kawasaki H
    Hepatogastroenterology; 1998; 45(23):1777-80. PubMed ID: 9840147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Octreotide in the treatment of refractory ascites of cirrhosis.
    Kalambokis G; Fotopoulos A; Economou M; Tsianos EV
    Scand J Gastroenterol; 2006 Jan; 41(1):118-21. PubMed ID: 16373285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Octreotide in the outpatient therapy of cirrhotic chylous ascites: a case report.
    Berzigotti A; Magalotti D; Cocci C; Angeloni L; Pironi L; Zoli M
    Dig Liver Dis; 2006 Feb; 38(2):138-42. PubMed ID: 16389001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial haemodynamic and renal sodium handling effects of combined midodrine and octreotide treatment in a cirrhotic patient with large hepatic hydrothorax and mild ascites.
    Kalambokis G; Fotopoulos A; Economou M; Tsianos EV
    Nephrol Dial Transplant; 2005 Nov; 20(11):2583. PubMed ID: 16105868
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of octreotide on renal function in patients with advanced cirrhosis.
    Fierbinţeanu-Braticevici C; Udeanu M; Usvat R; Andronescu D
    Rom J Intern Med; 2004; 42(1):173-81. PubMed ID: 15529607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study.
    Spahr L; Giostra E; Frossard JL; Morard I; Mentha G; Hadengue A
    Am J Gastroenterol; 2007 Jul; 102(7):1397-405. PubMed ID: 17488248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using octreotide for refractory ascites after liver transplantation.
    Nutu OA; Manrique Municio A; Marcacuzco Quinto A; Calvo Pulido J; Jiménez Romero C
    Rev Esp Enferm Dig; 2019 Nov; 111(11):882-884. PubMed ID: 31595758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe congenital chylothorax treated with octreotide.
    Young S; Dalgleish S; Eccleston A; Akierman A; McMillan D
    J Perinatol; 2004 Mar; 24(3):200-2. PubMed ID: 15044932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis and concomitant portal vein thrombosis.
    Van Ha TG; Hodge J; Funaki B; Lorenz J; Rosenblum J; Straus C; Leef J
    Cardiovasc Intervent Radiol; 2006; 29(5):785-90. PubMed ID: 16850140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chylous ascites caused by portal vein thrombosis treated with octreotide.
    Leong RW; House AK; Jeffrey GP
    J Gastroenterol Hepatol; 2003 Oct; 18(10):1211-3. PubMed ID: 12974913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effectiveness of the treatment of octreotide on chylous ascites after liver cirrhosis.
    Zhou DX; Zhou HB; Wang Q; Zou SS; Wang H; Hu HP
    Dig Dis Sci; 2009 Aug; 54(8):1783-8. PubMed ID: 19051030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Octreotide for palliative treatment of bleeding from unresectable gastric cancer.
    Sanaka M; Yamamoto T; Kawakami T; Kuyama Y
    Hepatogastroenterology; 2005; 52(64):2 p preceding I. PubMed ID: 16001612
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful treatment of repaglinide-induced hypoglycemia with octreotide.
    Fasano CJ; Rowden AK
    Am J Emerg Med; 2009 Jul; 27(6):756.e3-4. PubMed ID: 19751648
    [No Abstract]   [Full Text] [Related]  

  • 15. Scopolamine butylbromide plus octreotide in unresponsive bowel obstruction.
    Mercadante S
    J Pain Symptom Manage; 1998 Nov; 16(5):278-80. PubMed ID: 9846021
    [No Abstract]   [Full Text] [Related]  

  • 16. Octreotide as an agent for the relief of malignant ascites in palliative care patients.
    Cairns W; Malone R
    Palliat Med; 1999 Sep; 13(5):429-30. PubMed ID: 10659116
    [No Abstract]   [Full Text] [Related]  

  • 17. Can octreotide be the first line treatment for chylothorax?
    Leelahanon S; Petlek W; Sontimuang W; Pochanart P; Tepakorn V; Ruangpeg S
    J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S741-5. PubMed ID: 14700175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spontaneous neonatal chylothorax treated with octreotide.
    Siu SL; Lam DS
    J Paediatr Child Health; 2006; 42(1-2):65-7. PubMed ID: 16487393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Portal vein thrombosis: a predictable milestone in cirrhosis?
    Garcia-Pagan JC; Valla DC
    J Hepatol; 2009 Oct; 51(4):632-4. PubMed ID: 19660824
    [No Abstract]   [Full Text] [Related]  

  • 20. Octreotide enhances portal pressure reduction induced by propranolol in cirrhosis: a randomized, controlled trial.
    Vorobioff JD; Ferretti SE; Zangroniz P; Gamen M; Picabea E; Bessone FO; Reggiardo V; Diez AR; Tanno M; Cuesta C; Tanno HE
    Am J Gastroenterol; 2007 Oct; 102(10):2206-13. PubMed ID: 17608776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.